Celldex Therapeutics (CLDX) News Today $18.40 +0.61 (+3.41%) As of 10:10 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period 17,244 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by ExodusPoint Capital Management LPExodusPoint Capital Management LP bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 17,244 shares of tApril 15 at 4:21 AM | marketbeat.comAnalysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Target Price at $54.33April 10, 2025 | americanbankingnews.comCelldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year Low - Should You Sell?Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month Low - Here's WhyApril 9, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of "Moderate Buy" from AnalystsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has asApril 8, 2025 | marketbeat.comCinctive Capital Management LP Increases Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Cinctive Capital Management LP grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 140.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,320 shares of the biopharmaceutical company'sApril 5, 2025 | marketbeat.com23,790 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by Bryce Point Capital LLCBryce Point Capital LLC acquired a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 23,790 shares of the biopharmaceutiApril 5, 2025 | marketbeat.comWellington Management Group LLP Sells 267,766 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Wellington Management Group LLP decreased its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 8,975,833 shares of the biopharmaceutical company's stock after selling 26April 4, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Shares Down 6.5% - Here's What HappenedCelldex Therapeutics (NASDAQ:CLDX) Stock Price Down 6.5% - Here's WhyApril 3, 2025 | marketbeat.comPictet Asset Management Holding SA Sells 48,273 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Pictet Asset Management Holding SA lowered its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 4.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,090,173 shares of the biopharmaceutical cApril 2, 2025 | marketbeat.comAmerican Century Companies Inc. Has $15.38 Million Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)American Century Companies Inc. increased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 46.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 608,457 shares of the biopharmaceutical cApril 2, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Hits New 12-Month Low - Time to Sell?Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year Low - Here's What HappenedApril 1, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Trading Down 3.7% - Here's WhyCelldex Therapeutics (NASDAQ:CLDX) Trading Down 3.7% - Here's What HappenedMarch 26, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Purchased by Fox Run Management L.L.C.Fox Run Management L.L.C. boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 149.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,290 shares of the biopharmaceutical company's stock after buying an additMarch 25, 2025 | marketbeat.comCelldex initiated with an Overweight at Morgan StanleyMarch 21, 2025 | markets.businessinsider.comCelldex Therapeutics (NASDAQ:CLDX) Now Covered by Morgan StanleyMorgan Stanley started coverage on shares of Celldex Therapeutics in a research report on Thursday. They issued an "overweight" rating and a $46.00 price objective for the company.March 21, 2025 | marketbeat.comMorgan Stanley Initiates Coverage of Celldex Therapeutics (CLDX) with Overweight RecommendationMarch 21, 2025 | msn.com3CLDX : 7 Analysts Have This To Say About Celldex TherapeuticsMarch 21, 2025 | benzinga.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by BrokeragesCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has earned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, five have given a buy rMarch 13, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Estimate for CLDX EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceuMarch 7, 2025 | marketbeat.comCelldex presents preclinical data from CDX-622 at AAAAI 2025March 4, 2025 | markets.businessinsider.comCelldex Therapeutics to Present at Upcoming Investor ConferencesMarch 4, 2025 | globenewswire.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Fisher Asset Management LLCFisher Asset Management LLC raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 20.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 452,497 shares of the biopharmaceutical company's stock after buying an additional 78,145 shareMarch 4, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Reaches New 52-Week Low Following Analyst DowngradeCelldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year Low After Analyst DowngradeMarch 3, 2025 | marketbeat.comCelldex Therapeutics Inc (CLDX) Announces Promising Preclinical Data for CDX-622March 3, 2025 | gurufocus.comThe Goldman Sachs Group Has Lowered Expectations for Celldex Therapeutics (NASDAQ:CLDX) Stock PriceThe Goldman Sachs Group cut their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research note on Monday.March 3, 2025 | marketbeat.comCelldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025March 3, 2025 | globenewswire.comFY2028 Earnings Estimate for CLDX Issued By Leerink PartnrsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2028 EPS estimates for Celldex Therapeutics in a research note issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical coMarch 3, 2025 | marketbeat.comQ1 Earnings Forecast for CLDX Issued By HC WainwrightCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Celldex Therapeutics in a research note issued to investors on Friday, February 28th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceuMarch 3, 2025 | marketbeat.comCelldex announces data from Phase 2 barzolvolimab studiesMarch 2, 2025 | markets.businessinsider.comCelldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients ...March 1, 2025 | gurufocus.comCelldex Therapeutics Inc (CLDX) Reports Positive Phase 2 Results for Barzolvolimab in Chronic ...March 1, 2025 | gurufocus.comCelldex Therapeutics Inc (CLDX) Reports Positive Phase 2 Results for Barzolvolimab in Chronic ...March 1, 2025 | gurufocus.comCelldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025March 1, 2025 | investing.comCelldex Therapeutics Inc (CLDX) Reports Positive Phase 2 Results for Barzolvolimab in Chronic ...March 1, 2025 | gurufocus.comCelldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025March 1, 2025 | globenewswire.comCelldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In LineMarch 1, 2025 | finance.yahoo.comCelldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Friday.March 1, 2025 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for Celldex (CLDX)February 28, 2025 | markets.businessinsider.comCelldex Therapeutics (NASDAQ:CLDX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPSCelldex Therapeutics (NASDAQ:CLDX - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%.February 28, 2025 | marketbeat.comDecoding Celldex Therapeutics Inc (CLDX): A Strategic SWOT InsightFebruary 28, 2025 | gurufocus.comCelldex Therapeutics Inc (CLDX) Reports 2024 Financial Results and Provides Corporate UpdateFebruary 27, 2025 | gurufocus.comCelldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate UpdateFebruary 27, 2025 | globenewswire.comCelldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year Low - What's Next?Celldex Therapeutics (NASDAQ:CLDX) Hits New 52-Week Low - What's Next?February 25, 2025 | marketbeat.comCelldex Therapeutics (CLDX) Expected to Announce Quarterly Earnings on MondayCelldex Therapeutics (NASDAQ:CLDX) will be releasing earnings before the market opens on Monday, February 24, Financial Modeling Prep reports.February 17, 2025 | marketbeat.comBrokers Issue Forecasts for CLDX Q1 EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Celldex Therapeutics in a note issued to investors on Thursday, February 13th. Leerink Partnrs analyst T. Smith anticipates that the biopharmaceutical company will post earnFebruary 15, 2025 | marketbeat.comTSP Capital Management Group LLC Has $5.64 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)TSP Capital Management Group LLC lessened its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 9.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 223,343 sFebruary 15, 2025 | marketbeat.comKynam Capital Management, LP Increases Stake in Celldex Therapeutics IncFebruary 15, 2025 | gurufocus.comUBS Initiates Coverage of Celldex Therapeutics (CLDX) with Buy RecommendationFebruary 14, 2025 | msn.comCelldex initiated with a Buy at UBSFebruary 13, 2025 | markets.businessinsider.comUBS Group Initiates Coverage on Celldex Therapeutics (NASDAQ:CLDX)UBS Group began coverage on Celldex Therapeutics in a research note on Thursday. They set a "buy" rating and a $44.00 price target for the company.February 13, 2025 | marketbeat.com Remove Ads Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Media Mentions By Week CLDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼0.720.80▲Average Medical News Sentiment CLDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼44▲CLDX Articles Average Week Remove Ads Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ionis Pharmaceuticals News Alkermes News Amicus Therapeutics News Ligand Pharmaceuticals News BioCryst Pharmaceuticals News Dynavax Technologies News MannKind News Innoviva News Novavax News OPKO Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLDX Stock Free CLDX Stock Alerts